P2RY12 and diabetes mellitus: However, in patients without diabetes, 3-month DAPT (P2Y12 inhibitor) was associated with a lower risk of primary outcomes compared with both 3-month DAPT (aspirin) (OR: 0.57; CrI: 0.37–0.98) and 12-month DAPT (OR: 0.61; CrI: 0.45–0.92).